TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12376583

Group type: EXPERIMENTAL
Intervention: Binge meal consumption in subjects with BED
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Binge meal consumption in more-obese subjects with BED
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Normal meal consumption in subjects with BED
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Satiety ratings after binge meals in subjects with BED
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Energy intake from fat in obese subjects
Number of subjects: 42
Study: 10199878

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 26

Group type: COMPARATOR
Intervention: Pacing
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Isoproterenol infusion
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Physiological pacing rates
Number of subjects: 26
Study: 7784009

Group type: EXPERIMENTAL
Intervention: Cadaver dissection course (n=7)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control group (n=6)
Number of subjects: 13
Study: 1601341

Group type: EXPERIMENTAL
Intervention: Chevron osteotomy alone
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Chevron osteotomy with adductor tenotomy
Number of subjects: 38
Study: 2864945

Group type: EXPERIMENTAL
Intervention: Vecuronium bromide administered after pancuronium bromide
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Pancuronium bromide administered during vecuronium-induced partial neuromuscular blockade
Number of subjects: 40
Study: 30659073

Group type: EXPERIMENTAL
Intervention: Visit-to-visit variability (VVV) of fasting blood glucose (FBG) defined as the SD of FBG measurements (≥26.4 mg/dL)
Number of subjects: 4982

Group type: EXPERIMENTAL
Intervention: Visit-to-visit variability (VVV) of fasting blood glucose (FBG) defined as variability independent of the mean (VIM)
Number of subjects: 4982

Group type: EXPERIMENTAL
Intervention: Highest quartile of SD of FBG among individuals without diabetes
Number of subjects: 4982

Group type: EXPERIMENTAL
Intervention: Highest quartile of VIM among individuals without diabetes
Number of subjects: 4982
Study: 30327287

Group type: EXPERIMENTAL
Intervention: Single ProGlide/Glubran technique for vascular access-site closure
Number of subjects: 250
Study: 26315474

Group type: EXPERIMENTAL
Intervention: Indoor smoking ban with not more than 10 cigarettes/day
Number of subjects: 141

Group type: COMPARATOR
Intervention: Indoor smoking ban with at least 11 cigarettes/day
Number of subjects: 141

Group type: COMPARATOR
Intervention: Homes without an indoor smoking ban
Number of subjects: 141

Group type: COMPARATOR
Intervention: Follow-up sample of homes without a ban
Number of subjects: 141
Study: 24779384

Group type: COMPARATOR
Intervention: No mention of the funding source or CoI
Number of subjects: 354

Group type: COMPARATOR
Intervention: Reporting the funding source only
Number of subjects: 354

Group type: COMPARATOR
Intervention: Reporting the funding source and CoI
Number of subjects: 354
Study: 23138807

Group type: EXPERIMENTAL
Intervention: Chewing gum
Number of subjects: 98

Group type: COMPARATOR
Intervention: Ibuprofen
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Trial administration
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Overall time spent on the trial
Number of subjects: 98
Study: 19627407

Group type: EXPERIMENTAL
Intervention: Mechanical massage (MM)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Manual lymphatic drainage (MLD)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Connective tissue manipulation (CTM)
Number of subjects: 60
Study: 18622248

Group type: EXPERIMENTAL
Intervention: Method 1 (including papillary muscles and trabeculae in myocardium)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Method 2 (excluding papillary muscles and trabeculae from myocardium)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Papillary muscles and trabeculae mass
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Difference in ejection fraction
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ventricular mass index
Number of subjects: 60
Study: 16420135

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group therapy (CBGT)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Clinical case management (CCM)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: CBGT + CCM
Number of subjects: 67

Group type: COMPARATOR
Intervention: CBGT
Number of subjects: 67

Group type: COMPARATOR
Intervention: All 3 conditions
Number of subjects: 67
Study: 11838623

Group type: EXPERIMENTAL
Intervention: Reboxetine (6 to 8 mg/day)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Reboxetine
Number of subjects: 82
Study: 9272406

Group type: EXPERIMENTAL
Intervention: Valsartan (160 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Furosemide (40 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Combined treatment (Valsartan + Furosemide)
Number of subjects: 12
Study: 7514046

Group type: EXPERIMENTAL
Intervention: Erythropoietin (Epo) 600 U/kg three times per week
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Erythropoietin (Epo) and G-CSF
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo and G-CSF
Number of subjects: 35
Study: 3069882

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 35

Group type: COMPARATOR
Intervention: Amitriptyline and Nortriptyline
Number of subjects: 35
Study: 29252039

Group type: EXPERIMENTAL
Intervention: Whey Protein (WP) 35g
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo (PLA) 35g
Number of subjects: 31
Study: 27105016

Group type: EXPERIMENTAL
Intervention: Prolonged Exposure Therapy for Adolescents (PE-A)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Client-Centered Therapy (CCT)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Both PE-A and CCT
Number of subjects: 61
Study: 25148231

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 23581800

Group type: EXPERIMENTAL
Intervention: Project U‐Turn, a comprehensive sex education program
Number of subjects: 973

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 973
Study: 19756902

Group type: EXPERIMENTAL
Intervention: Capacitive coupling electrical stimulation by Osteospine (active group)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Low intensity pulse (control group)
Number of subjects: 51
Study: 19109497

Group type: EXPERIMENTAL
Intervention: transcranial random noise stimulation (tRNS)
Number of subjects: 80
Study: 16607188

Group type: EXPERIMENTAL
Intervention: Exposed group (welding fumes)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (nonexposed)
Number of subjects: 22
Study: 12732600

Group type: EXPERIMENTAL
Intervention: Arginine vasopressin (AVP) combined with norepinephrine (NE)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Norepinephrine (NE) alone
Number of subjects: 48
Study: 10976551

Group type: EXPERIMENTAL
Intervention: Quinidine sulfate (200 mg single oral dose)
Number of subjects: 42
Study: 8470716

Group type: EXPERIMENTAL
Intervention: Acuvue disposable contact lens
Number of subjects: 37

Group type: COMPARATOR
Intervention: CSI traditional daily-wear lens
Number of subjects: 37

Group type: COMPARATOR
Intervention: CSI lens
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Acuvue lens
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Overall lens preference
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Lens comfort
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Lens handling
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Rate or cost of torn lenses
Number of subjects: 37
Study: 3543073

Group type: EXPERIMENTAL
Intervention: Lactate 12% lotion applied twice daily for 4 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 0

Group type: COMPARATOR
Intervention: Petrolatum cream
Number of subjects: 0
Study: 29523562

Group type: EXPERIMENTAL
Intervention: Electronic Epworth Sleepiness Scale (ESS)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Paper Epworth Sleepiness Scale (ESS)
Number of subjects: 112
Study: 25893397

Group type: EXPERIMENTAL
Intervention: Neuromuscular taping (NT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham tape
Number of subjects: 40
Study: 25842933

Group type: EXPERIMENTAL
Intervention: MARS
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Prometheus
Number of subjects: 26
Study: 22445938

Group type: EXPERIMENTAL
Intervention: Preparation with polyethylene glycol on the morning of the colonoscopy (study group)
Number of subjects: 282

Group type: COMPARATOR
Intervention: Preparation with polyethylene glycol on the previous afternoon (control group)
Number of subjects: 282
Study: 20457556

Group type: EXPERIMENTAL
Intervention: Knowledge of financial incentive (£10 Amazon gift voucher)
Number of subjects: 485

Group type: COMPARATOR
Intervention: No knowledge of financial incentive
Number of subjects: 485
Study: 18721702

Group type: EXPERIMENTAL
Intervention: Molecular biology technique (PCR testing)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Traditional Gram stain and organism culture
Number of subjects: 29
Study: 16356801

Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg/day)
Number of subjects: 10305

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10305
Study: 12033657

Group type: EXPERIMENTAL
Intervention: Risk Skills Training Program (RSTP)
Number of subjects: 300

Group type: COMPARATOR
Intervention: No intervention control group
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Drug Abuse and Resistance Education (DARE-A)
Number of subjects: 300
Study: 10715368

Group type: EXPERIMENTAL
Intervention: Ethinyl estradiol in triphasic combination with norgestimate
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Gestodene
Number of subjects: 37
Study: 8924393

Group type: EXPERIMENTAL
Intervention: Video test for assessing interviewing skills
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standardized patients
Number of subjects: 0
Study: 2026464

Group type: EXPERIMENTAL
Intervention: Level I T, 150-300 mg (n = 24)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Level II T, 450-600 mg (n = 25)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo (n = 9)
Number of subjects: 58
Study: 7390209

Group type: EXPERIMENTAL
Intervention: Coordinated home services (experimental condition)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 71
Study: 30612986

Group type: EXPERIMENTAL
Intervention: Tapinarof 1% twice daily
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Tapinarof 1% once daily
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Tapinarof 0.5% twice daily
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Tapinarof 0.5% once daily
Number of subjects: 227

Group type: COMPARATOR
Intervention: Vehicle twice daily
Number of subjects: 227

Group type: COMPARATOR
Intervention: Vehicle once daily
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Tapinarof (all groups)
Number of subjects: 227

Group type: COMPARATOR
Intervention: Vehicle (all groups)
Number of subjects: 227
Study: 28103935

Group type: EXPERIMENTAL
Intervention: Active recruitment strategies
Number of subjects: 301

Group type: COMPARATOR
Intervention: Passive recruitment strategies
Number of subjects: 301
Study: 26286707

Group type: EXPERIMENTAL
Intervention: Training Group (TG) - 20 weeks of physical exercise training, 3 sessions of 20 minutes per week, focusing on neck and shoulder muscles.
Number of subjects: 69

Group type: COMPARATOR
Intervention: Reference Group (RG) - No training.
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Training Group (TG)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Reference Group (RG)
Number of subjects: 69
Study: 24024772

Group type: EXPERIMENTAL
Intervention: Oatmeal
Number of subjects: 48

Group type: COMPARATOR
Intervention: RTEC
Number of subjects: 48
Study: 20532541

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (AC)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Misoprostol (M)
Number of subjects: 67
Study: 18798237

Group type: EXPERIMENTAL
Intervention: Transradial (TR) approach
Number of subjects: 307

Group type: COMPARATOR
Intervention: Transfemoral (TF) approach
Number of subjects: 307
Study: 16604127

Group type: EXPERIMENTAL
Intervention: Glycerol-induced hyperhydration (GIH) - 1.2 g glycerol/kg bodyweight with 26 mL/kg BW of water-aspartame-flavored fluid
Number of subjects: 6

Group type: COMPARATOR
Intervention: Water-induced hyperhydration (WIH) - water-aspartame-flavored fluid only
Number of subjects: 6
Study: 14523363

Group type: EXPERIMENTAL
Intervention: Thymalin
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Epithalamin
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Thymalin plus Epithalamin
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Thymalin plus Epithalamin (annual treatment for 6 years)
Number of subjects: 266

Group type: COMPARATOR
Intervention: Control
Number of subjects: 266
Study: 10945039

Group type: EXPERIMENTAL
Intervention: Chloroquine plus sulfadoxine-pyrimethamine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chloroquine alone
Number of subjects: 0
Study: 8866204

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Streptokinase during 1 h (1,500,000 U)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Streptokinase during 48 h (250,000 U for 1 h and then 100,000 U for 48 h)
Number of subjects: 100
Study: 1631487

Group type: EXPERIMENTAL
Intervention: Power toothbrushing
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Manual toothbrushing with conventional fluoride toothpaste
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Chlorhexidine/fluoride gel
Number of subjects: 14
Study: 6091840

Group type: EXPERIMENTAL
Intervention: Intravenous bicarbonate (150 mmol)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Intravenous saline
Number of subjects: 16
Study: 28456864

Group type: EXPERIMENTAL
Intervention: Sci-B-Vac™ (10 μg, 3 doses at 0, 1, and 6 months for naïve patients; 20 μg for previously vaccinated non-responders)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Engerix B® (40 μg, 4 doses at 0, 1, 2, and 6 months)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Sci-B-Vac™
Number of subjects: 86

Group type: COMPARATOR
Intervention: Engerix B®
Number of subjects: 86
Study: 27250846

Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN; receiving conventional perioperative management via a CVC)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Peripheral parenteral nutrition (PPN; receiving perioperative management without a CVC)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Peripheral parenteral nutrition (PPN)
Number of subjects: 40
Study: 25636499

Group type: EXPERIMENTAL
Intervention: Anxiety sensitivity cognitive concerns
Number of subjects: 106

Group type: COMPARATOR
Intervention: Negative affect
Number of subjects: 106

Group type: COMPARATOR
Intervention: Thwarted belongingness and insomnia
Number of subjects: 106
Study: 24152421

Group type: EXPERIMENTAL
Intervention: Increased spacing and eventual discontinuation of TNF blockers after 6 months
Number of subjects: 180

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 180
Study: 21185726

Group type: EXPERIMENTAL
Intervention: Isometric muscle strength of the lower limbs measured using hand held dynamometry (Nm/kg)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 3D gait analysis using VICON system
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Assessment of muscle strength
Number of subjects: 25
Study: 18729243

Group type: EXPERIMENTAL
Intervention: Garcinia cambogia (2.4 g) plus Amorphophallus konjac (1.5 g)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 17296074

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Promotion of one's coping resources therapy
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Social support
Number of subjects: 60

Group type: COMPARATOR
Intervention: Waiting list
Number of subjects: 60
Study: 12806521

Group type: EXPERIMENTAL
Intervention: Triptans (various formulations including oral tablets, orally disintegrating tablets, nasal sprays, subcutaneous injections, suppositories)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 10735929

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg once daily
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg once daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: Theophylline alone
Number of subjects: 30
Study: 8813266

Group type: EXPERIMENTAL
Intervention: Transjugular intrahepatic portasystemic stent shunts (TIPS)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Small-diameter prosthetic H-graft portacaval shunts (HGPCS)
Number of subjects: 70
Study: 1444879

Group type: EXPERIMENTAL
Intervention: Oxiracetam
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 4061004

Group type: EXPERIMENTAL
Intervention: Adrenaline 0.5 mg i.v.
Number of subjects: 65

Group type: COMPARATOR
Intervention: Phenylephrine 1.0 mg i.v.
Number of subjects: 65
Study: 30831180

Group type: EXPERIMENTAL
Intervention: Higher energy density (increased by 20%)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Lower energy density (decreased by 20%)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Baseline energy density
Number of subjects: 49
Study: 30089680

Group type: EXPERIMENTAL
Intervention: EHR alert activation
Number of subjects: 2987

Group type: COMPARATOR
Intervention: Control group (no alert)
Number of subjects: 2987
Study: 26864436

Group type: EXPERIMENTAL
Intervention: Fasting (60 hours)
Number of subjects: 12
Study: 25225037

Group type: EXPERIMENTAL
Intervention: Potentially real cigarettes
Number of subjects: 64

Group type: COMPARATOR
Intervention: Hypothetical cigarettes
Number of subjects: 64
Study: 22517217

Group type: EXPERIMENTAL
Intervention: Azelnidipine (AZ) 16 mg
Number of subjects: 2

Group type: COMPARATOR
Intervention: Amlodipine (AM) 5 mg
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 2
Study: 19733100

Group type: EXPERIMENTAL
Intervention: Brief behavioral intervention (6-minute intervention video)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Standardized care (Control)
Number of subjects: 121
Study: 18612741

Group type: EXPERIMENTAL
Intervention: Didactic training plus participation as educators in a community-based IPV prevention program
Number of subjects: 117

Group type: COMPARATOR
Intervention: Didactic training only
Number of subjects: 117
Study: 16374022

Group type: EXPERIMENTAL
Intervention: Impermeable bed covers
Number of subjects: 32

Group type: COMPARATOR
Intervention: Cotton covers (Control)
Number of subjects: 32
Study: 12631365

Group type: EXPERIMENTAL
Intervention: Paricalcitol
Number of subjects: 263

Group type: COMPARATOR
Intervention: Calcitriol
Number of subjects: 263
Study: 10966962

Group type: EXPERIMENTAL
Intervention: Buffered solution (solution B) - 5 ml 2% lignocaine and 5 ml 0.5% bupivacaine with pH 7.44
Number of subjects: 60

Group type: COMPARATOR
Intervention: Plain solution (solution A) - 5 ml 2% lignocaine and 5 ml 0.5% bupivacaine (acidic)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 8839902

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with cyclophosphamide, methotrexate and fluorouracil (CMF)
Number of subjects: 90

Group type: COMPARATOR
Intervention: No further treatment (Control)
Number of subjects: 90
Study: 1401309

Group type: EXPERIMENTAL
Intervention: Etretinate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cyclosporine
Number of subjects: 0
Study: 6652049

Group type: EXPERIMENTAL
Intervention: Vacuum extraction
Number of subjects: 304

Group type: COMPARATOR
Intervention: Forceps delivery
Number of subjects: 304
Study: 31182696

Group type: EXPERIMENTAL
Intervention: Fibrin sealant application (no drain)
Number of subjects: 262

Group type: COMPARATOR
Intervention: Drain (group A)
Number of subjects: 262
Study: 30322505

Group type: EXPERIMENTAL
Intervention: Nurse-led care program
Number of subjects: 116

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 116
Study: 26994949

Group type: EXPERIMENTAL
Intervention: Regional Anesthesia (RA)
Number of subjects: 1151

Group type: EXPERIMENTAL
Intervention: General Anesthesia (GA)
Number of subjects: 1151

Group type: COMPARATOR
Intervention: Carotid Artery Stenting (CAS)
Number of subjects: 1151
Study: 23756431

Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (A-tDCS) for 10 minutes at 1 mA in the DLPFC, followed by rehabilitative cognitive training, daily for 15 days
Number of subjects: 23

Group type: COMPARATOR
Intervention: Sham A-tDCS for 25 seconds with the same rehabilitation
Number of subjects: 23
Study: 21705170

Group type: EXPERIMENTAL
Intervention: Nurse education intervention (1‐h, one‐on‐one teaching session with a nurse educator)
Number of subjects: 227

Group type: COMPARATOR
Intervention: Standard discharge process (control group)
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Nurse education intervention
Number of subjects: 227
Study: 19386430

Group type: EXPERIMENTAL
Intervention: Tegafur-uracil (300 mg/m²/d) and leucovorin (75 mg/d) from Days 1 to 19 and from Days 29 to 47, carboplatin (70 mg/m² intravenously for 4 consecutive days), in three cycles every 21 days, with radiotherapy (70 Gy in 35 fractions)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Tegafur-uracil, leucovorin, and carboplatin
Number of subjects: 72
Study: 16690005

Group type: EXPERIMENTAL
Intervention: Paroxetine (20 mg/d)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Venlafaxine (150 mg/d)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Venlafaxine (300 mg/d)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Desipramine (100 mg/d)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Nefazodone (300 mg/d)
Number of subjects: 4
Study: 16081626

Group type: EXPERIMENTAL
Intervention: Balance group (BAL) - energy and carbohydrate replaced during exercise
Number of subjects: 16

Group type: COMPARATOR
Intervention: Deficit group (DEF) - energy not replaced during exercise
Number of subjects: 16
Study: 12151999

Group type: EXPERIMENTAL
Intervention: 200 mg efavirenz
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 400 mg efavirenz
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12